Amplitude Inc Class A AMPL

A number of stocks jumped in the afternoon session after the Bureau of Economic Analysis reported a 0.9% increase in personal consumption expenditures for August, signaling resilient consumer demand alongside steady economic expansion.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the data analytics industry, including Amplitude (NASDAQ:AMPL) and its peers.

A number of stocks fell in the afternoon session after markets remained volatile during the last trading session of the week, reflecting growing uncertainty, with the broad market retreat erasing the sector's gains from the previous day.

A number of stocks jumped in the afternoon session after shares of enterprise software and SaaS companies rallied broadly as investors rotated capital out of semiconductor and AI-hardware stocks following calls for an artificial intelligence development slowdown.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Motive raised more than $1.3 billion from General Catalyst after crossing $600 million ARR and 30% growth, and withdrew its S-1. The post Motive raises $1.3 billion from General Catalyst appeared first on FreightWaves.

Amplitude (AMPL) has drawn fresh attention after recent trading saw the stock move sharply over the past 3 months, while shares fell 3.9% in the latest session and 8.9% over the past week. Set against an 81.6% 3 month share price return and a 19.1% year to date share price return, the latest pullback in Amplitude at a share price of $13.02 suggests momentum has cooled in the very short term, even though the 1 year total shareholder return of 13.9% and 3 year total shareholder return of 2.9%...

Amplitude stock has delivered a positive year to date return while investors are getting conflicting valuation messages, with an intrinsic value estimate pointing to upside and market based multiples leaning the other way. Year to date the share price is up 19.1%, which means recent buyers have already seen a solid gain going into any valuation work. The key support for a higher intrinsic value is the Discounted Cash Flow, which can benefit if Amplitude converts more of its revenue into...

A number of stocks jumped in the afternoon session after software equities broadly gained momentum following a pullback in treasury yields and second-quarter financial results from Snowflake.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

A number of stocks jumped in the afternoon session after quarterly earnings and upbeat corporate commentary signaled that artificial intelligence is driving growth across enterprise software rather than threatening legacy business models.

The software stock selloff may have just reached a turning point.

Software is eating the world, and virtually no business is left untouched by it. The undeniable tailwinds fueling the industry have also led to strong returns for SaaS stocks lately as they’ve gained 51.5% over the past six months, outpacing the S&P 500’s 12.7% rise.

Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company ("Lilly") to discover and develop taRNA vaccine candidates for infectious diseases. The collaboration will initially focus on undisclosed infectious disease vaccine programs with high unmet need, with Lilly retaining the option to add up to two additional infectious disease targets.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.